应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01530 三生制药
交易中 07-24 09:35:45
6.490
+0.090
+1.41%
最高
6.510
最低
6.370
成交量
11.05万
今开
6.370
昨收
6.400
日振幅
2.19%
总市值
155.54亿
流通市值
155.54亿
总股本
23.97亿
成交额
71.69万
换手率
0.00%
流通股本
23.97亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
南向资金7月19日净卖出三生制药48.55万股 连续5日减持
自选股智能写手 · 07-22 09:31
南向资金7月19日净卖出三生制药48.55万股 连续5日减持
三生制药07月17日主力资金流入95万元 连续3日加仓
自选股智能写手 · 07-17
三生制药07月17日主力资金流入95万元 连续3日加仓
三生制药重组红细胞生成刺激蛋白注射液SSS06向国家药监局递交上市申请并获受理
美通社 · 07-12
三生制药重组红细胞生成刺激蛋白注射液SSS06向国家药监局递交上市申请并获受理
三生制药:长效促红素SSS06新药上市申请获受理
和讯网 · 07-12
三生制药:长效促红素SSS06新药上市申请获受理
三生制药(01530)1类新药申报上市获受理 用于治疗肾衰竭贫血
智通财经 · 07-12
三生制药(01530)1类新药申报上市获受理 用于治疗肾衰竭贫血
三生制药荣膺2024中国上市公司英华奖港股ESG价值奖
美通社 · 07-11
三生制药荣膺2024中国上市公司英华奖港股ESG价值奖
大摩:予三生制药(01530)“与大市同步”评级 目标价上调至8港元
智通财经 · 07-09
大摩:予三生制药(01530)“与大市同步”评级 目标价上调至8港元
《大行》大摩升三生制药(01530.HK)目标价至8元 评级“与大市同步”
阿斯达克财经 · 07-09
《大行》大摩升三生制药(01530.HK)目标价至8元 评级“与大市同步”
三生制药07月08日主力资金流出119万元 连续5日减仓
自选股智能写手 · 07-08
三生制药07月08日主力资金流出119万元 连续5日减仓
南向资金7月3日净卖出三生制药73.45万股 连续3日减持
自选股智能写手 · 07-04
南向资金7月3日净卖出三生制药73.45万股 连续3日减持
三生制药(01530.HK)6月28日耗资5802万港元回购906万股打开手机微信扫一扫
金融界 · 06-28
三生制药(01530.HK)6月28日耗资5802万港元回购906万股打开手机微信扫一扫
三生制药(01530)6月28日耗资约5802.18万港元回购906万股
智通财经 · 06-28
三生制药(01530)6月28日耗资约5802.18万港元回购906万股
三生制药(01530)6月27日斥资2056.17万港元回购328.15万股
智通财经 · 06-27
三生制药(01530)6月27日斥资2056.17万港元回购328.15万股
三生制药(01530)6月26日斥资977.2万港元回购156.05万股
智通财经 · 06-26
三生制药(01530)6月26日斥资977.2万港元回购156.05万股
三生制药(01530)上涨5.32%,报6.34元/股
金融界 · 06-26
三生制药(01530)上涨5.32%,报6.34元/股
三生制药(01530)股价上升5.15%,现价港币$6.33
阿斯达克财经 · 06-26
三生制药(01530)股价上升5.15%,现价港币$6.33
三生制药盘中异动 临近收盘快速上涨5.00%报6.321港元
自选股智能写手 · 06-26
三生制药盘中异动 临近收盘快速上涨5.00%报6.321港元
三生制药6月25日斥资约1025.13万港元回购170.75万股
新浪港股 · 06-26
三生制药6月25日斥资约1025.13万港元回购170.75万股
三生制药(01530)6月25日斥资约1025.13万港元回购170.75万股
智通财经网 · 06-25
三生制药(01530)6月25日斥资约1025.13万港元回购170.75万股
三生制药(01530)委任张皎娥为非执行董事
智通财经网 · 06-25
三生制药(01530)委任张皎娥为非执行董事
暂无数据
公司概况
公司名称:
三生制药
所属市场:
SEHK
上市日期:
--
主营业务:
三生制药是一家主要从事开发、生产、营销及销售医药产品的投资控股公司。该公司的主要产品包括重组人血小板生成素产品,肿瘤坏死因子α抑制剂产品以及重组人促红素等。产品以特比澳,益赛普,益比奥,以及赛博尔等品牌销售。该公司在国内市场和斯里兰卡、多米尼加共和国及泰国等海外市场销售产品。该公司的子公司包括集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司。该公司通过其子公司还从事项目管理及咨询业务。
发行价格:
--
{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":6.49,"timestamp":1721784938613,"preClose":6.4,"halted":0,"volume":110500,"delay":0,"floatShares":2396668912,"shares":2396668912,"eps":0.68061763,"marketStatus":"交易中","marketStatusCode":2,"change":0.09,"latestTime":"07-24 09:35:45","open":6.37,"high":6.51,"low":6.37,"amount":716880,"amplitude":0.021875,"askPrice":6.5,"askSize":19000,"bidPrice":6.49,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":0.6691507065594252,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1721793600000},"adr":0,"adjPreClose":6.4,"dividendRate":0.037458,"openAndCloseTimeList":[[1721784600000,1721793600000],[1721797200000,1721808000000]],"volumeRatio":1.840498,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530/tweets","defaultTab":"tweets","newsList":[{"id":"2453785568","title":"南向资金7月19日净卖出三生制药48.55万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2453785568","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453785568?lang=zh_cn&edition=full","pubTime":"2024-07-22 09:31","pubTimestamp":1721611888,"startTime":"0","endTime":"0","summary":"7月19日,南向资金减持三生制药48.55万股连续5日减持。截止当日收盘,港股通共持有三生制药77036.01万股,占流通股31.87%。港股通减持金额前五个股分别为中国海洋石油、中国石油股份、中国宏桥、中国移动、中广核电力。三生制药近5个交易日下跌2.96%,港股通累计减持367.73万股;近20个交易日上涨7.72%,港股通累计减持281.51万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407220942329edd54ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407220942329edd54ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","01530","BK1593"],"gpt_icon":0},{"id":"2452187814","title":"三生制药07月17日主力资金流入95万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452187814","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452187814?lang=zh_cn&edition=full","pubTime":"2024-07-17 16:16","pubTimestamp":1721204207,"startTime":"0","endTime":"0","summary":"07月17日, 三生制药股价涨0.30%,报收6.61元,成交金额1950万元,换手率0.12%,振幅1.21%,量比0.65。三生制药今日主力资金净流入95万元,连续3日净流入,上一交易日主力净流入60万元,今日环比增加58.33%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为54.55%,平均涨幅为2.72%。该股近5个交易日上涨1.22%,主力资金累计净流入304万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出761万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716172795cd6cda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716172795cd6cda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01530","BK1161","BK1593"],"gpt_icon":0},{"id":"2450887302","title":"三生制药重组红细胞生成刺激蛋白注射液SSS06向国家药监局递交上市申请并获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2450887302","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450887302?lang=zh_cn&edition=full","pubTime":"2024-07-12 17:42","pubTimestamp":1720777320,"startTime":"0","endTime":"0","summary":"沈阳2024年7月12日 /美通社/ -- 三生制药今天宣布,公司自主研发的长效促红素产品重组红细胞生成刺激蛋白注射液SSS06已向国家药监局递交上市申请并获受理,用于治疗正在接受促红细胞生成素治疗的成人透析患者。对于血液透析的慢性肾衰竭患者而言,及时纠正血红蛋白水平,可使患者的生存质量和生理功能得到显著改善。同时,作为新一代长效促红素产品,SSS06将为患者提供更加便利的用药选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4460251_ZH60251_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","BK1593","BK1161","01530"],"gpt_icon":0},{"id":"2450823375","title":"三生制药:长效促红素SSS06新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2450823375","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450823375?lang=zh_cn&edition=full","pubTime":"2024-07-12 11:39","pubTimestamp":1720755585,"startTime":"0","endTime":"0","summary":"快讯正文【三生制药新药上市申请获受理】7月12日,中国国家药监局药品审评中心(CDE)官网公示,三生制药的重组红细胞生成刺激蛋白注射液(CHO细胞)新药上市申请已获受理。三生制药此前宣布,其长效促红素SSS06的3期临床研究已达到预设主要终点,计划近期向NMPA递交新药上市申请。SSS06是一款高糖基化长效重组蛋白产品,通过基因重组技术增加3个N-糖基化位点,具有较长的稳定性和半衰期,能减少用药次数,方便临床使用。三生制药已完成一项多中心、随机、平行对照3期临床试验,统计结果显示,试验组与对照组在有效性及安全性上无明显差异。下载和讯APP查看快讯,体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121402359f39aa8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121402359f39aa8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1593","01530"],"gpt_icon":0},{"id":"2450732803","title":"三生制药(01530)1类新药申报上市获受理 用于治疗肾衰竭贫血","url":"https://stock-news.laohu8.com/highlight/detail?id=2450732803","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450732803?lang=zh_cn&edition=full","pubTime":"2024-07-12 10:19","pubTimestamp":1720750756,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,7月12日,中国国家药监局药品审评中心官网公示,三生制药的重组红细胞生成刺激蛋白注射液已提交新药上市申请并获受理。而在今年1月,三生制药已经宣布其长效促红素SSS06的一项用于治疗血液透析的慢性肾衰竭贫血患者的3期临床研究达到了预设主要终点。三生制药在彼时的新闻稿中表示,计划于近期向NMPA递交新药上市申请。试验组与对照组在不良事件的发生率及严重程度上无明显差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1583","BK1161","01530"],"gpt_icon":0},{"id":"2450357980","title":"三生制药荣膺2024中国上市公司英华奖港股ESG价值奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2450357980","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450357980?lang=zh_cn&edition=full","pubTime":"2024-07-11 20:52","pubTimestamp":1720702320,"startTime":"0","endTime":"0","summary":"论坛现场同步揭晓了2024中国上市公司英华示范案例获奖名单。中国生物制药领军企业三生制药荣膺港股ESG价值奖。2024中国上市公司英华示范案例评选由中国基金报发起,旨在秉承新\"国九条\"精神,从长期投资、价值投资视角出发,全面客观地评估企业的综合实力与价值,评选出获得机构投资者认可的上市公司。员工人均培训小时数20.90小时,董事会成员反贪污培训覆盖率100%,MSCI ESG评级稳居AA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4459398_ZH59398_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["YANG","01530","BK1161","ESG","BK1583","BK1593"],"gpt_icon":0},{"id":"2450050290","title":"大摩:予三生制药(01530)“与大市同步”评级 目标价上调至8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450050290","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450050290?lang=zh_cn&edition=full","pubTime":"2024-07-09 11:48","pubTimestamp":1720496935,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,大摩发布研究报告称,予三生制药(01530)“与大市同步”评级,上调毛利率,以反映TPIAO的增长加速,令毛利有所提高。将三生制药的2024至2026每股盈利预测上调5%、5%及4%,目标价由7.5港元上调至8港元。该行指出,将三生制药2024至2026年销售预测每年上调4%,主要由于对特比澳(TPIAO)、红血球生成素(EPO)、HER2与盐酸纳呋拉啡(REMITCH)较高的销售假设,部分被蔓迪(Mandi)及CDMO业务的销售下降所抵销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1147530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530"],"gpt_icon":0},{"id":"2450052702","title":"《大行》大摩升三生制药(01530.HK)目标价至8元 评级“与大市同步”","url":"https://stock-news.laohu8.com/highlight/detail?id=2450052702","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450052702?lang=zh_cn&edition=full","pubTime":"2024-07-09 10:59","pubTimestamp":1720493940,"startTime":"0","endTime":"0","summary":"摩根士丹利发表报告指出,将三生制药(01530.HK) 2024至2026年销售预测每年上调4%,主要由于对特比澳(TPIAO)、红血球生成素(EPO)、HER2与盐酸纳呋拉啡(REMITCH)较高的销售假设,部分被蔓迪(Mandi)及CDMO业务的销售下降所抵销。此外,该行上调对三生制药的毛利率,以反映TPIAO的增长加速,令毛利有所提高。该行亦将三生制药的2024至2026每股盈利预测上调5%、5%及4%,目标价由7.5元上调至8元,评级“与大市同步”。(jl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-08 16:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190627151657886_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190627151657886_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362238/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01530"],"gpt_icon":0},{"id":"2449725836","title":"三生制药07月08日主力资金流出119万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2449725836","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449725836?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:15","pubTimestamp":1720426507,"startTime":"0","endTime":"0","summary":"07月08日, 三生制药股价跌2.33%,报收6.30元,成交金额1459万元,换手率0.10%,振幅3.10%,量比0.39。三生制药今日主力资金净流出119万元,连续5日净流出,上一交易日主力净流出86万元,今日环比增加38.37%。近一年数据显示,该股主力连续5日净流出后,次日下跌概率为14.29%,平均跌幅为3.60%。该股近5个交易日下跌1.71%,主力资金累计净流出660万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出667万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708161514958f1f5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708161514958f1f5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2448469445","title":"南向资金7月3日净卖出三生制药73.45万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2448469445","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448469445?lang=zh_cn&edition=full","pubTime":"2024-07-04 09:31","pubTimestamp":1720056692,"startTime":"0","endTime":"0","summary":"7月3日,南向资金减持三生制药73.45万股连续3日减持。截止当日收盘,港股通共持有三生制药76971.62万股,占流通股31.83%。港股通减持金额前五个股分别为中国神华、汇丰控股、波司登、中国电力、安踏体育。三生制药近5个交易日上涨6.64%,港股通累计减持486.30万股;近20个交易日上涨2.56%,港股通累计增持1311.95万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040941299571c782&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040941299571c782&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1593","01530","BK1583"],"gpt_icon":0},{"id":"2446504699","title":"三生制药(01530.HK)6月28日耗资5802万港元回购906万股打开手机微信扫一扫","url":"https://stock-news.laohu8.com/highlight/detail?id=2446504699","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446504699?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:19","pubTimestamp":1719577189,"startTime":"0","endTime":"0","summary":"格隆汇6月28日丨 三生制药(01530.HK)公告,6月28日耗资5802万港元回购906万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406282024209f70d4ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406282024209f70d4ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1593","01530"],"gpt_icon":0},{"id":"2446501897","title":"三生制药(01530)6月28日耗资约5802.18万港元回购906万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446501897","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446501897?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:11","pubTimestamp":1719576700,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药(01530)公布,2024年6月28日耗资约5802.18万港元回购906万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1593","01530"],"gpt_icon":0},{"id":"2446582072","title":"三生制药(01530)6月27日斥资2056.17万港元回购328.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446582072","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446582072?lang=zh_cn&edition=full","pubTime":"2024-06-27 18:31","pubTimestamp":1719484301,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药(01530)发布公告,于2024年6月27日该公司斥资2056.17万港元回购328.15万股,回购价格为每股6.2-6.3港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","01530","BK1593"],"gpt_icon":0},{"id":"2446300367","title":"三生制药(01530)6月26日斥资977.2万港元回购156.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446300367","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446300367?lang=zh_cn&edition=full","pubTime":"2024-06-26 20:20","pubTimestamp":1719404415,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药(01530)发布公告,于2024年6月26日斥资977.2万港元回购156.05万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2446358769","title":"三生制药(01530)上涨5.32%,报6.34元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446358769","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446358769?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:43","pubTimestamp":1719387806,"startTime":"0","endTime":"0","summary":"6月26日,三生制药(01530)盘中上涨5.32%,截至15:43,报6.34元/股,成交2860.92万元。三生制药是一家主要致力于开发、生产和销售医药产品,产品包括重组人血小板生成素、肿瘤坏死因子α抑制剂以及重组人促红素等,销售市场涵盖国内以及斯里兰卡、多米尼加共和国和泰国等海外市场。此外,公司通过其子公司集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司也从事项目管理和咨询业务。截至2023年年报,三生制药营业总收入78.16亿元、净利润15.49亿元。6月24日,公司以每股5.88-6港元回购125.7万股,回购金额747万港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/26154341210619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01530","BK1593","BK1583","BK1161"],"gpt_icon":0},{"id":"2446935395","title":"三生制药(01530)股价上升5.15%,现价港币$6.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2446935395","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446935395?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:43","pubTimestamp":1719387780,"startTime":"0","endTime":"0","summary":"[上升股]三生制药(01530) 股价在下午03:43比前收市价上升5.15%,现股价为港币$6.33。至目前为止,今日最高价为$6.33,而最低价为$6.02。总成交量为459.65万股,总成交金额为港币$2.844千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406261290/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01530","BK1161","BK1593","BK1583"],"gpt_icon":0},{"id":"2446335802","title":"三生制药盘中异动 临近收盘快速上涨5.00%报6.321港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446335802","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446335802?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:42","pubTimestamp":1719387766,"startTime":"0","endTime":"0","summary":"2024年06月26日临近收盘15时42分,三生制药股票出现异动,股价大幅上涨5.00%。截至发稿,该股报6.321港元/股,成交量452.7万股,换手率0.19%,振幅4.98%。三生制药股票所在的药品行业中,整体涨幅为0.28%。其相关个股中,中国医疗集团、泰凌医药、三生制药涨幅较大,振幅较大的相关个股有泰凌医药、中国医疗集团、君圣泰医药-B,振幅分别为15.62%、14.14%、13.50%。消息层面,截至15时42分,三生制药股票正面舆情新闻比例100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062615424696817099&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062615424696817099&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1593","01530","BK1583"],"gpt_icon":0},{"id":"2446805723","title":"三生制药6月25日斥资约1025.13万港元回购170.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446805723","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446805723?lang=zh_cn&edition=full","pubTime":"2024-06-26 07:46","pubTimestamp":1719359188,"startTime":"0","endTime":"0","summary":"三生制药(01530)发布公告,于2024年6月25日斥资约1025.13万港元回购股份170.75万股,每股回购价格为5.97-6.04港元。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-06-26/doc-inazzfpt6420670.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-06-26/doc-inazzfpt6420670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2446405608","title":"三生制药(01530)6月25日斥资约1025.13万港元回购170.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446405608","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446405608?lang=zh_cn&edition=full","pubTime":"2024-06-25 22:53","pubTimestamp":1719327195,"startTime":"0","endTime":"0","summary":"三生制药(01530)发布公告,于2024年6月25日斥资约1025.13万港元回...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_41.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_41.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1583","BK1593","01530"],"gpt_icon":0},{"id":"2446684058","title":"三生制药(01530)委任张皎娥为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2446684058","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446684058?lang=zh_cn&edition=full","pubTime":"2024-06-25 22:50","pubTimestamp":1719327018,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药(01530)公布,张丹由于其他业务承诺,退任独立非执行董事职务,自股东周年大会结束时生效。黄斌因已达到退休年龄,已辞任非执行董事职务,自2024年6月25日起生效。同日起,张皎娥已获委任为非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062522520895d6ddb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062522520895d6ddb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","01530","BK1593"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":0.0961},{"period":"3month","weight":0.1412},{"period":"6month","weight":0.0998},{"period":"1year","weight":-0.1033},{"period":"ytd","weight":-0.1152}],"compareEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":-0.031},{"period":"3month","weight":0.0156},{"period":"6month","weight":0.0776},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":0.0248}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"三生制药是一家主要从事开发、生产、营销及销售医药产品的投资控股公司。该公司的主要产品包括重组人血小板生成素产品,肿瘤坏死因子α抑制剂产品以及重组人促红素等。产品以特比澳,益赛普,益比奥,以及赛博尔等品牌销售。该公司在国内市场和斯里兰卡、多米尼加共和国及泰国等海外市场销售产品。该公司的子公司包括集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司。该公司通过其子公司还从事项目管理及咨询业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.00277},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.015935},{"month":3,"riseRate":0.777778,"avgChangeRate":0.064866},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.015967},{"month":5,"riseRate":0.666667,"avgChangeRate":0.057469},{"month":6,"riseRate":0.777778,"avgChangeRate":0.012147},{"month":7,"riseRate":0.1,"avgChangeRate":-0.074538},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.005781},{"month":9,"riseRate":0.555556,"avgChangeRate":0.015553},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.008495},{"month":11,"riseRate":0.777778,"avgChangeRate":0.073643},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.037252}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}